BRAF and metastatic melanoma: Based on the COMBI-v trial (dabrafenib plus trametinib vs. vemurafenib) (21) and COMBI-d trial (dabrafenib plus trametinib to dabrafenib) (22), the 5-year progression-free survival rates and overall rates for unresectable or metastatic melanoma with a BRAF V600 mutation treated with dabrafenib plus trametinib as first-line therapy were 19% and 34%, respectively (23).